Single Chamber Atrial Leadless Pacing for Isolated Sinus Node Dysfunction
1 other identifier
observational
50
1 country
6
Brief Summary
The study aims to evaluate the following: 1) the incidence of new onset atrial fibrillation in patients with an atrial leadless pacemaker, 2) the need for upgrade from a standalone atrial leadless pacemaker to a dual chamber leadless pacemaker system, and 3) to compare the battery longevity of the Aveir AR at two years with the battery longevity of subjects implanted with dual chamber leadless pacemakers in the Aveir DR i2i study.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started May 2026
Typical duration for all trials
6 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 18, 2026
CompletedFirst Submitted
Initial submission to the registry
June 5, 2026
CompletedFirst Posted
Study publicly available on registry
June 10, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 18, 2029
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2029
June 10, 2026
June 1, 2026
3 years
June 5, 2026
June 5, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Incidence of atrial fibrillation
Incidence of atrial fibrillation in patients implanted with a single chamber (Aveir AR, Abbott) leadless pacemaker and a loop recorder.
24 months
Secondary Outcomes (3)
Composite incidence of a newly prolonged PR interval
24 months
Need for system upgrade from a single chamber to dual chamber
24 months
Battery Longevity
24 months
Interventions
Implantation of a loop recorder in subjects with sick sinus syndrome and normal atrioventricular conduction who are receiving an atrial leadless pacemaker as standard of care.
Eligibility Criteria
1. 50 patients who receive an Aveir AR device as standard of care 2. Patients willing to receive an Assert-IQ loop recorder for research purposes 3. All sexes 4. Age \> 18 years old 5. Able to provide written informed consent
You may qualify if:
- Symptomatic sinus bradycardia
- Sino-atrial exit block
- Symptomatic sinus arrest with sinus pauses \> 2 sec during waking hours
- Symptomatic sinus bradycardia \< 40 bpm for \> 1 min during waking hours
- PR interval ≤ 0.22 sec if aged \< 70 years or PR interval ≤ 0.26 sec if aged ≥ 70 years
- QRS width ≤ 0.12 sec
- No prior PM implantation
- Patients willing to receive an Assert-IQ loop recorder for research purposes
You may not qualify if:
- Atrioventricular block
- Bundle branch block
- History of atrial fibrillation
- Carotid sinus hypersensitivity
- Planned cardiac surgery
- Estimated life expectancy \< 1 year
- Presence of an existing ventricular pacemaker or implantable cardioverter defibrillator
- Known acute deep vein thrombosis of either lower extremity
- Unable to read or write
- Patient with Limited English Proficiency (LEP)
- Cognitively impaired individuals
- Pregnant
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Northwell Healthlead
- Abbottcollaborator
Study Sites (6)
South Shore University Hospital
Bay Shore, New York, 11706, United States
Huntington Hospital
Huntington, New York, 11743, United States
North Shore University Hospital
Manhasset, New York, 11030, United States
Long Island Jewish Medical Center
New Hyde Park, New York, 11040, United States
Lenox Hill Hospital
New York, New York, 10075, United States
Staten Island University Hospital
Staten Island, New York, 10305, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
James Gabriels, MD
Northwell Health
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 5, 2026
First Posted
June 10, 2026
Study Start
May 18, 2026
Primary Completion (Estimated)
May 18, 2029
Study Completion (Estimated)
December 31, 2029
Last Updated
June 10, 2026
Record last verified: 2026-06